Fig. 6: miR-293-5p therapy slowed obesity in mice.

A Male C57BL/6 J mice were administered a high-fat diet and subjected to a protocol involving tail vein injection of either agomir miR-293-5p or miR-NC. B The body weight of the mice described in (A) was recorded, with each group comprising n = 5 mice. C The fat mass of the mice in (A) was measured, with each group consisting of n = 5 mice. D Rectal temperature was assessed in the mice from (A) when exposed to a 4°C environment, with n = 5 mice per group. E-G. Serum concentrations of triglycerides (E), total cholesterol (F), and free fatty acids (G) were evaluated in the mice from (A), with n = 5 mice per group. H A glucose tolerance test was conducted following the high-fat diet regimen in the mice from (A), with n = 5 mice per group. I An insulin tolerance test was performed subsequent to high-fat diet feeding in the mice from (A), with n = 5 mice per group. J UCP1 protein levels were quantified in BAT through n = 3 independent experiments. K Male C57BL/6 J mice underwent indirect calorimetry analysis under basal conditions, with each group containing n = 5 mice. L Hematoxylin and eosin (H&E) staining was performed on samples from the mice in (A) across different treatment groups, with a scale bar of 0.2 mm for BAT.